ProMIS Neurosciences, Inc. (PMN) Company Revenue

Is it worth investing in ProMIS Neurosciences (PMN), given the venture risks and dependence on patents for AI-driven antibody selection? Optimization via external CDMO plants minimizes downtime, while the company's sales figures help identify hidden revenue declines. The current value of 0.00 shows the actual magnitude of the metric. Looking ahead, ProMIS Neurosciences (PMN) is counting on insurance payouts for innovative dementia therapy targeting toxic proteins.

PMN ProMIS Neurosciences: Revenue and Sales Volume in the range 06/27/2023 - 11/13/2026

Analytical breakdowns for ProMIS Neurosciences

- market price and analyst price targets:

Market Price ProMIS|PMN - Price Target Chart

- market capitalization details:

Market Value ProMIS Neurosciences, Inc.|PMN - Total Company Value

- book capitalization information:

Net Asset Value per Share ProMIS Neurosciences|PMN - Book Capitalization|Market Value to Equity Ratio promisneurosciences.com|PMN - Cumulative Company Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

PMN - Net Profit|Company Profit Forecast ProMIS Neurosciences|PMN - Price to Earnings Ratio|Market Cap to Projected Earnings ProMIS|PMN - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation ProMIS Neurosciences, Inc.|PMN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months ProMIS Neurosciences|PMN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months promisneurosciences.com|PMN - Net earnings per share growth this year|Earnings growth forecast for next year ProMIS Neurosciences

- company sales and revenue statistics:

PMN - Company Revenue|Company Future Revenue ProMIS|PMN - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio ProMIS Neurosciences, Inc.

Comprehensive company analysis:promisneurosciences.com - PMN

Original product of ProMIS Neurosciences Inc.

Long-term investing requires strict control over an issuer's operational stability by monitoring cash inflows. For ProMIS Neurosciences (PMN), whose viability depends on the outcomes of Alzheimer's therapy clinical trials, the absence of regular income creates elevated risks. The company's aggregate sales level reflects the sum of daily transactions, allowing for a real-time assessment of any changes in commercial activity. This indicator determines the current stage of technology monetization and the overall investment attractiveness of the asset.

Analysis of competing companies